─ 231 ─ (CABG 3.8% vs. PCI 9.7% ; p < 0.0001) and repeat revascularization (CABG 13.7% vs. PCI 25.9% ; p < 0.0001) were significantly lower with CABG than PCI. A recent, randomized, non-inferiority trial compared second-generation drug-eluting stents using everolimus with CABG in patients with multivessel disease 9). At 2 years, the primary endpoint (composite of death, myocardial infarction, or target vessel revascularization) had occurred in 11.0% of PCI patients and in 7.9% of CABG patients (absolute risk difference 3.1 percentage points ; 95% confidence interval [CI]-0.8-6.9 ; p = 0.32 for noninferiority). However, at longer-term follow-up (median 4.6 years), the primary endpoint had occurred in 15.3% of the PCI group and in 10.6% of the CABG group (hazard ratio (HR) 1.47 ; 95% CI 1.01-2.13 ; p = 0.04). The rates of spontaneous myocardial infarction and new-lesion revascularization were greater with PCI than with CABG-differences that emerged early and continued to increase throughout the follow-up period. Another study using New York registry data compared shortand long-term outcomes with the propensity-score matching method between PCI with everolimus-eluting stents and CABG in patients with multivessel coronary disease 10). At a mean follow-up of 2.9 years, PCI compared with CABG was associated with a similar risk of death (PCI 3.1% per year, CABG 2.9% per year ; HR 1.04 ; 95% CI 0.93-1.17 ; p = 0.50), significantly higher risk of myocardial infarction (PCI 1.9% per year, CABG